Cresp 200mcg (Darbepoetin alfa)

Darbepoetin alfa
Contact us for more information
Wishlist Compare
Dr. Reddy’s Laboratories

Cresp 200mcg (Darbepoetin alfa)

ManufacturerDr. Reddy’s LaboratoriesBrand nameCrespActive substanceDarbepoetin alfaStrength200mcgCategoryNephrologyManufacturerDr.Reddy's

Description of Cresp 200mcg (Darbepoetin alfa 200mcg)

Cresp 200mcg (Darbepoetin alfa 200mcg) is a man-made form of a protein which promote your body form red blood cells. This protein may be decreased when you have kidney failure or use certain regimens. When lesser red blood cells are formed, which develop a condition called Anemia.
Darbepoetin alfa is necessary to cure Anemia occurred by chemotherapy or chronic kidney disease.

Medical use /Indication of Cresp 200mcg (Darbepoetin alfa 200mcg)

Cresp 200mcg (Darbepoetin alfa 200mcg) is prescribed for the treatment in patients with Anemia associated with chronic kidney disease (CKD).
Cresp 200mcg (Darbepoetin alfa 200mcg) is prescribed for the therapy in patients with Anemia is caused by chemotherapy cancer treatment but it is a support medication, it will not treat cancer
Cresp 200mcg (Darbepoetin alfa 200mcg) is prescribed for the therapy in patients with Symptomatic Anemia along with myelodysplastic syndromes (MDS).

Mechanism of Action Cresp 200mcg (Darbepoetin alfa 200mcg)

Darbepoetin alfa activate erythropoiesis by exciting the division and differentiation of committed erythroid progenitor cells; produce the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes. There is a dose-reaction relationship with this effect. This results in araise in reticulocyte counts pursue by aincrease in haematocrit and hemoglobin levels.

ADME of Cresp 200mcg (Darbepoetin alfa 200mcg)

Absorption: slow

Time to maximum plasma concentration: 34 hr subcutaneously (SC)

Bioavailability for adult: 37% SC and

Bioavailability for children: 54% SC

Volume of distribution: 0.06L/kg

Half-life is 46 hr (SC) and

if IV then 21 hr.

Side effects of Cresp 200mcg (Darbepoetin alfa 200mcg)

Cresp 200mcg (Darbepoetin alfa 200mcg) as some of the side effects as follows;

  • Hypertension
  • Seizures
  • Serious allergic reaction: wheezing, dizziness, skin rash, itching
  • Shortness of breath
  • Cough
  • Low blood pressure during dialysis
  • Pain in abdominal
  • Edema of the arms or legs

Precautions of Cresp 200mcg (Darbepoetin alfa 200mcg)

  • While Reduction of dose if Hgb has high exceeds 1 g/dL in any 2-week period
  • Increased the mortality and/or higher the risk of tumor progression or relapsed in patients with cancer
  • When treatment with Cresp 200mcg (Darbepoetin alfa 200mcg)has high risk for seizures in patients with CKD; high checking of these patients for alter in seizure frequency or premonitory symptoms
  • If serious Anemia and low reticulocyte count occurs during treatment, withhold treatment and check out for pure red cell aplasia.
  • When treatment with Cresp 200mcg (Darbepoetin alfa 200mcg)injection will causes high mortality, myocardial infarction, stroke, and thromboembolism: Using ESAs to target a haemoglobin level of greater than 11 g/dL raises the risk of severe adverse cardiovascular reactions
  • When treatment with Cresp 200mcg (Darbepoetin alfa 200mcg) injection will leads to known porphyria, sickle cell Anemia, thalassemia in patients

Drug interaction of Cresp 200mcg (Darbepoetin alfa 200mcg)

No drug interaction involved in the medicine Cresp 200mcg (Darbepoetin alfa 200mcg) Injection

Contraindication of Cresp 200mcg (Darbepoetin alfa 200mcg)

The patients contraindicated with Cresp 200mcg (Darbepoetin alfa 200mcg) injection causes

  • Severe hypertension
  • After treatment results in pure red cell aplasia
  • Allergic problem

Pregnancy of Cresp 200mcg (Darbepoetin alfa 200mcg)

Pregnancy category is C
Less available data on pregnant women are lacking to decide a medicine-associated risk of major birth defects or miscarriage. So avoid using Cresp 200mcg (Darbepoetin alfa 200mcg) foe pregnant women

Lactation of Cresp 200mcg (Darbepoetin alfa 200mcg)

During breastfeeding using Cresp 200mcg (Darbepoetin alfa 200mcg) has no adequate studies in women for determine infant harm. Considered probable risk before taking the medicine while breastfeeding

Dosage of Cresp 200mcg (Darbepoetin alfa 200mcg)

The usual dose of this medicine will be changed for different patients.

Anemia from chronic kidney failure :

  • The dose considered for adults and children – dose chiefly based on body weight
  • Initial treatment: The prescribed dose is 0.45 to 0.75 mcg/kg of body weight injected through IV or SC (under the skin) once a week or once every week.
  • Your doctor may adjust the dose as required

Anemia from cancer chemotherapy :

  • For adult: dose is based on body weight
  • Initial treatment: The usual dose is 2.25mcg once every 3 weeks injected under the skin.
  • The dose for children and use should be determined by your doctor

Storage of Cresp 200mcg (Darbepoetin alfa 200mcg)

Store at 2℃ – 8℃ (36℉ to 46℉) Do not freeze Protect from light and protect from light

Missed dose of Cresp 200mcg (Darbepoetin alfa 200mcg)

If dose is forget to take then have it soon before next dose reaches or leave the missed dose and follow normal timing
Please Consult with the doctor

Brand name:
Active substance:
Darbepoetin alfa
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India